

Enabling new, essential and valuable
chemicals via

Cell-Free Biomanufacturing



invizyne

FORWARD-LOOKING STATEMENTS

This presentation contains “forward-looking” information. The information indicates expected future business and financial performance and financial condition. Forward-looking statements address matters that are uncertain. Forward-looking statements are not guarantees of future performance or financial condition, and are only based on management’s current expectations, assumptions, estimates and projections about the Company and the industry segments in which the Company operate. The statements that are forward looking are subject to the risks and uncertainties that the Company will face, many of which are discussed in the Registration Statement on Form S-1 filed with the Securities and Exchange Commission, for the offering. You are urged to consider these risk factors in evaluating your investment in the Company.

The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity.

The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission. The securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.

We obtained industry, marketing and competitive position data in this presentation from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. While we believe that the statistical data, market data and other industry data and forecasts are reliable we have not independently verified the data.

Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.

Listing securities entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. If the Company is unable to satisfy these obligations, of which there can be no assurance, the common stock may be delisted. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at the following location [EDGAR Entity Landing Page \(sec.gov\)](#).

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, not will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

CURRENT MANUFACTURING OF CHEMICALS

invizyne

The world is using **unsustainable and inefficient** manufacturing processes to make fuels, foods, medicines, and other products via...

**Petroleum-Based
Manufacturing**

**Plant-Derived
Products**

**1st Generation
Synthetic Biology**


All these processes suffer from fundamental problems and bottlenecks

INVIZYNE'S DISRUPTIVE SOLUTION: CELL-FREE BIOMANUFACTURING

invizyne


Changes the paradigm of chemical manufacturing by taking the enzyme pathway out of the cell

CELLS ARE COMPLEX & UNFOCUSED



Only ~5% of energy goes into chemical production

CELL-FREE OPTIMIZES PERFORMANCE



All energy goes into chemical production

INVIZYNE'S DISRUPTIVE SOLUTION: CELL-FREE BIOMANUFACTURING

invizyne

Enables chemical and drug companies to turn natural resources into valuable chemicals **sustainably and affordably**

Key Advantages:

New & Better Products

- Enables new products and markets
- Chemicals that otherwise can not be made
- New and better versions of existing chemicals at better prices

Environmentally Sustainable

- Lowers carbon emissions
- Lowers pollution
- Uses plant-based sugars and starches to create valuable chemicals

Low Production Costs

- Lower CAPEX
- Higher yields
- Less downstream processing
- Fast R&D cycles

Fast Time-To-Market

- Rapid design, testing and proof of feasibility makes it cost-effective
- No toxicity concerns because no fragile cells to keep alive

Demonstrated Approach

- Moving to commercial production scale with more products after demonstrating manufacturing scaling feasibility

INVIZYNE'S DISRUPTIVE SOLUTION: CELL-FREE BIOMANUFACTURING

invizyne

Recognized leader of Cell-Free Biomanufacturing in peer-reviewed scientific journals

3X published in



4X published in




INVIZYNE'S DISRUPTIVE SOLUTION: CELL-FREE BIOMANUFACTURING


invizyne

Demonstrated **game-changing improvements** in manufacturing feasibility versus competitors


Flavors/Fragrances - Terpenes



Pharmaceuticals - CBGA



Biofuels - Isobutanol




Footnotes

- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221582/>
- <https://www.proactiveinvestors.com/companies/news/960900/willow-biosciences-ramps-up-production-titer-delivers-corporate-update-960900.html>
- <https://www.ieabioenergy.com/blog/publications/progress-in-the-commercialization-of-biojet-sustainable-aviation-fuels-technologies-potential-and-challenges/>

DE-RISKING PROCESS AT INVIZYNE

invizyne

Developing **cell-free biomanufacturing solutions** ready for commercialization



CAPITAL EFFICIENT BUSINESS MODEL

invizyne

\$13MM+ in grants enabling and accelerating the development of platform technology



Cannabinoids
Phase I SBIR \$150k

Cannabinoids
Phase II SBIR \$2MM

Methylation
Phase I SBIR \$255k



Cofactors
Phase II SBIR \$2MM

Isobutanol
BETO \$2.1MM + \$3.7MM

Alcohols
ARPAe \$1.6MM

Proteins
ARPAe SBIR \$500k

Cofactors
Phase IIb \$1.2MM




Proteins
TCF \$150k

Cell-Free
Subcontract \$50k

COMMERCIALIZATION STRATEGY

invizyne



INTELLECTUAL PROPERTY POSITION

invizyne

Business model leverages IP for **proprietary processes, key enzymes and novel chemicals**

10+ *patents and substantial trade secrets* protecting:

Novel Cell-Free
Biomanufacturing



Novel
Enzymes



Novel & Rare
Chemicals




Advanced AI &
R&D Platform



PARTNERSHIP & BUSINESS DEVELOPMENT PRIORITIZATION

invizyne

Focus on opportunities and markets that **create value for shareholders**



POTENTIAL PARTNERS BY MAJOR VERTICAL

invizyne

PHARMA/APIs



FOOD/FLAVORS/FRAGRANCES



ENERGY TRANSITION/BIOFUELS




INDUSTRIAL CHEMICALS



*Please note: This is not meant to be considered a list of current customers/partners, but rather examples of partnership candidates.

PARTNERSHIP DEAL FUNNEL OPTIMIZATION

invizyne



Key Considerations

- Discernment in deal selection
- Balanced funnel dynamics
- Continuous replenishment
- Efficient transition and progression
- Quality over quantity
- Strategic abandonment


DEMONSTRATED MARKET OPPORTUNITY #1: RENEWABLE CHEMICALS/BIOFUELS

invizyne

Isobutanol used as Sustainable Aviation Fuel (SAF)

- A liquid fuel already used in commercial aviation, which reduces CO₂ emissions by up to 80%
- Comprises less than 0.1% of aviation fuels, but **all airlines are looking for suppliers**
- Healthy premiums/subsidies paid for SAF over fossil fuels
- A **politically mandated hyper-growth** market in both US and EU
- 70% of jet fuels at EU airports mandated to be SAF by 2050

Total Addressable Market (U.S.)



Source: The International Air Transport Association (IATA.org) and Acumen Research and Consulting

DEMONSTRATED MARKET OPPORTUNITY #2: PHARMA

invizyne

Cell-free, enzyme-based biomanufacturing for **drug discovery and development**

- Enables new and better drugs **otherwise impossible to make**
- Allows for the biochemical engineering and mass production of a new generation of complex drug molecules, **by overcoming the limitations of cellular metabolism** and first-generation synthetic biology
- Allows for chemical engineering level control (biocatalysis) at never seen before levels by using **the best of biology and chemistry simultaneously**



BUSINESS MODEL WITH ASYMMETRIC UPSIDE POTENTIAL

invizyne

By partnering, instead of trying to compete, we have **multiple shots on goal in multiple markets**

Limited Downside



- Foundational patents
- Capital light
- Government grants and partners

Unlimited Upside



- Unlimited markets
- Multiple potential revenue streams License fees
 - Royalties (1%—8%)
 - Critical enzyme sales

High Impact on NPV




- Ability to disrupt multiple, multi-billion-dollar markets
- Potential value creation significant without the risk profile and cost of competing directly
- Potential to generate significant investor returns relative to capital requirement

KEY FOCUS AND USE OF PROCEEDS

invizyne

Five building blocks for the next three years



Scaling
Enzyme
Production



R&D Project &
Facilities
Expansion



Expanding the
Team
of Talents



Growing
Isobutanol
Business Unit
& Partnerships



Growing
Pharma API
Business Unit &
Partnerships

OUR TEAM

invizyne

Experienced commercial leadership team including **the world's leading cell-free scientists**



**Michael
Heltzen**
CEO



**Tyler
Korman Ph.D.**
Co-Founder,
VP of Research



**Paul
Opgenorth Ph.D.**
Co-Founder, VP of
Development



**Michael
Burns**
EVP of Energy
Transition



**Zachary
Karl Ph.D.**
VP of Business
Development

+ an expert team of 20+ scientists, chemical engineers, technicians, and business development professionals

INVIZYNE IPO SUMMARY (UPDATE)

The Invizyne logo, featuring the word "invizyne" in a lowercase, sans-serif font. A green arrow points from the "INVIZYNE IPO SUMMARY (UPDATE)" header to the logo.

- + \$15.00 MM
- + \$4.00 per share
- + 3,750,000 shares
- + Proposed Ticker: IZTC
- + Allocation preference given to MDBH shareholders / account holders
- + Management believes IPO qualifies for Section 1202/QSBS exclusion*
- + Trading expected on NASDAQ next week, pending final SEC approval
- + Sept. 6th registration statement adds 2nd quarter financials and Long Term Investor Right

*You should consult your own tax, legal and accounting advisors before engaging in any transaction.

Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as "Nasdaq." The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.

Listing securities entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. If the Company is unable to satisfy these obligations, of which there can be no assurance, the common stock may be delisted. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at the following location EDGAR Entity Landing Page ([sec.gov](https://www.sec.gov)).

LONG TERM INVESTOR RIGHT (LTIR)

invizyne

Summary:

- Only applies to new shares purchased by investors in offering
- Each share now coupled with a non-transferable contractual right
- Right could allow the original IPO investor to obtain up to one additional share of common stock on the second anniversary of the closing date of the IPO – at no additional expense

Why Offered?

- Attracts and rewards investors aligned with long-term growth and success of business
- Compliments the potential QSBS 1202 benefit
- Compels company to reach value-creating collaboration and licensing milestones to minimize dilution

LONG TERM INVESTOR RIGHT (LTIR)

invizyne

Key Conditions:

- **Ownership:** To benefit from the LTIR, investors must...
 - Register shares within 90 days with the transfer agent in their name (not hold in “street name”) or hold in a brokerage account at original underwriters and selected dealers of the offering
 - Continuously hold shares during the two years after the IPO closing date
 - A sale or transfer will generally terminate the right
- **Triggers:** In the two years following the IPO closing date...
 - **Termination:** If IZTC shares **DO** trade at \$8.00 (or higher) on 20 trading days (consecutive or non-consecutive), the right is canceled.
 - **Grant:** If IZTC shares **DO NOT** trade at \$8.00 (or higher) on 20 trading days (consecutive or non-consecutive), the LTIR will convert to IZTC common shares based on a pre-determined formula.

LTIR EXAMPLE

invizyne

Formula:

Calculation 1:

$$\left(200\% \text{ of IPO price} - \text{Measurement Average Price}^* \right) / \text{Measurement Average Price}^* = \text{LTIR shares of IZTC common stock received}$$

Calculation 2:

$$\text{IZTC Shares purchased in IPO} \times \text{LTIR shares received} = \text{LTIR shares of IZTC common stock received}$$

*Measurement Average Price is the highest average of IZTC closing price on Nasdaq for any six-month period during the two-year holding period

LTIR EXAMPLE

invizyne

Example:

Calculation 1:

$$(\$8.00 - \$5.00) / \$5.00 = 0.6$$

200% of
IPO price

Measurement
Average Price*

Measurement
Average Price*

LTIR shares of IZTC common
stock received

Calculation 2:

$$1,000 \times 0.6 = 600$$

IZTC Shares
purchased in
IPO

LTIR shares
received

LTIR shares of IZTC common stock
received

*Measurement Average Price is the highest average of IZTC closing price on Nasdaq for any six-month period during the two-year holding period

INVIZYNE OWNERSHIP TABLE

invizyne

	PRE-IPO*	POST-IPO*
Total Shares (Issued, RSUs, SAFE)**	14,014,581	17,764,581
MDB Shares	8,272,851	8,272,851
<i>% Owned by MDBH</i>	<i>59.0%</i>	<i>46.6%</i>
Founders & Other Shares	5,741,730	5,741,730
<i>% Owned by Founders & Others</i>	<i>41.0%</i>	<i>32.3%</i>
New IPO Shares		3,750,000
<i>% Owned by IPO investors</i>		<i>21.0%</i>

*Beneficial ownership calculated under SEC rules

** Does not include options or LTIRs

Enabling the

Cell-Free Biomanufacturing Revolution

Learn more at invizyne.com
or contact:

Michael Heltzen
CEO

Invizyne Technologies Inc.
750 Royal Oaks Drive, Suite 106
Monrovia, CA 91016
Michael.H@Invizyne.com

©2024 Invizyne Technologies Inc.
All Rights Reserved



invizyne